BillionToOne, Inc. (NASDAQ: BLLN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $4.6B. The Maz Rating grades it against the other companies in its sector.
BillionToOne, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $96.31, BillionToOne, Inc. trades at 93.8x trailing earnings, 10.5x sales and 8.0x book value, with an EV/EBITDA of 70.7. Over the last twelve months it generated about $437M of revenue and $49M of net income. It runs a gross margin of 71.4%, an operating margin of 10.2% and a net margin of 11.3%. It shows return on equity of 9.5%, return on invested capital of 6.3% and a free cash flow yield of 0.7%. On the balance sheet: a debt-to-equity ratio of 0.25 and a current ratio of 11.25. Over the past 52 weeks the share price ranged from $61.96 to $150.44, with a beta of 0.34.
BillionToOne, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.